{"id":"W4416391584","doi":"10.1016/j.annonc.2025.09.032","title":"LBA22 Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; Eisai; Gilead Sciences; AstraZeneca; Gilead UK and Ireland Corporate Contributions; Pfizer","keywords":"Pembrolizumab; Metastatic breast cancer; Chemotherapy; Breast cancer; Phases of clinical research; Chemotherapy regimen","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001997136,0.0007608577,0.001408964,0.0003091287,0.0002213159,0.001195202,0.0004949669,0.0006901944,0.002707966],"category_scores_gemma":[0.001570551,0.0002258852,0.003401675,0.0004982425,0.0003273102,0.0008063902,0.0005222564,0.001950672,0.0005101899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006745401,"about_ca_system_score_gemma":0.0005136453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009981238,"about_ca_topic_score_gemma":0.002123981,"domain_scores_codex":[0.9990985,0.0004853882,0.00005797312,0.0001348777,0.00009175204,0.0001315223],"domain_scores_gemma":[0.9987813,0.0003264447,0.0005248838,0.00005324414,0.00004841161,0.0002657459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7944837,0.002758346,0.1073571,0.001567067,0.01942417,0.0001697915,0.0001305243,0.005767852,0.00515091,0.0004031776,0.005198218,0.05758922],"study_design_scores_gemma":[0.1447129,0.2033001,0.5960999,0.0005557901,0.0327859,0.0005988847,0.0003830245,0.006360505,0.003236315,0.001163776,0.0106483,0.0001547414],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853336,0.006961042,0.0002382419,0.0005390417,0.0001551138,0.0001590132,0.00424875,0.00003502071,0.002330074],"genre_scores_gemma":[0.9926924,0.001316136,0.0001750004,0.0004625887,0.0001357574,0.0002614952,0.003789091,0.000009893083,0.001157665],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002707966,"threshold_uncertainty_score":0.01056194,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02759695281756261,"score_gpt":0.3660159048530534,"score_spread":0.3384189520354908,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}